Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations
Open Access
- 25 February 2008
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 17 (3), 215-223
- https://doi.org/10.1002/pds.1545
Abstract
Purpose We present a new population-based pharmacoepidemiological (PE) database obtained from statutory health insurances (SHIs) that is able to generate signals, to monitor prescribed drugs and to describe drug utilisation. We discuss methodological features of the database and we assess to which degree this database reflects basic demographic characteristics and hospitalisation rates of the general population. Methods Files of three SHIs were linked with drug dispensation data from a pharmacies' electronic data processing centre on an individual basis using the unique subject identification number (ID) at a trusted third party centre. Plausibility checks and descriptive analyses were carried out. Results The database covers 3.6 million SHI-members, provides drug utilisation data and data on hospitalisations. SHI membership is fairly stable over time. Our data indicate marked differences in socio-demographic characteristics between SHIs. Hospital admission rates standardised for age vary between 0.164 and 0.229 per person year, which is in good agreement with official statistics (0.20). The age distribution shows good agreement for men and some underrepresentation for women above the age of 60 as compared to the general population. Conclusions Confounder information on medical conditions, concomitant medications and socio-demographic variables can be obtained from the database, while the assessment of confounders related to lifestyle requires supplementary data collection. The database allows for a population-based approach and reflects daily practice including off-label use of drugs. Independent recording of exposure and outcome data prevents reporting bias on medication or outcome. Legal conditions that allow continuous updating of the database need to be settled. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Hospitalization rates of generic metoprolol compared with the original beta‐blocker in an epidemiological database studyPharmacoepidemiology and Drug Safety, 2007
- PharmacoepidemiologyPublished by Springer Science and Business Media LLC ,2007
- Ethical Aspects of Epidemiological ResearchPublished by Springer Science and Business Media LLC ,2005
- Celecoxib in der symptomatischen Therapie bei aktivierter Osteoarthrose oder rheumatoider ArthritisDeutsche Medizinische Wochenschrift (1946), 2004
- Research use of linked health data — a best practice protocolAustralian and New Zealand Journal of Public Health, 2002
- Use of the mediplus patient database in healthcare research.Int. Journal of Clinical Pharmacology and Therapeutics, 2002
- Health Databases in SaskatchewanPublished by Wiley ,2000
- Use of the UK General Practice Research Database for pharmacoepidemiologyBritish Journal of Clinical Pharmacology, 1998
- The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in QuébecJournal of Clinical Epidemiology, 1995
- The role of automated record linkage in the postmarketing surveillance of drug safety: A critiqueClinical Pharmacology & Therapeutics, 1989